Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Current Taxes (2016 - 2025)

Historic Current Taxes for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to $1.9 million.

  • Ascendis Pharma A's Current Taxes rose 6868.56% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 6868.56%. This contributed to the annual value of $1.3 million for FY2024, which is 4653.04% down from last year.
  • Latest data reveals that Ascendis Pharma A reported Current Taxes of $1.9 million as of Q3 2025, which was up 6868.56% from $804823.3 recorded in Q2 2025.
  • Ascendis Pharma A's Current Taxes' 5-year high stood at $7.4 million during Q1 2023, with a 5-year trough of $96035.1 in Q2 2022.
  • Over the past 5 years, Ascendis Pharma A's median Current Taxes value was $1.2 million (recorded in 2024), while the average stood at $2.3 million.
  • In the last 5 years, Ascendis Pharma A's Current Taxes surged by 644589.86% in 2023 and then plummeted by 8417.74% in 2024.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Current Taxes stood at $226506.3 in 2021, then skyrocketed by 2372.85% to $5.6 million in 2022, then crashed by 55.84% to $2.5 million in 2023, then crashed by 47.21% to $1.3 million in 2024, then surged by 44.14% to $1.9 million in 2025.
  • Its Current Taxes was $1.9 million in Q3 2025, compared to $804823.3 in Q2 2025 and $1.7 million in Q1 2025.